Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

EADO Congress 2015

28 - 31 Oct 2015

Palais du Pharo, Marseille, France

What is the relationship between PD-L1 expression and antitumour activity?

Dr Paolo Ascierto - National Tumor Institute, Naples, Italy

What is the relationship between PD-L1 expression and antitumour activity? ( Dr Paolo Ascierto - National Tumor Institute, Naples, Italy )

Prognostic value of BRAFV600 mutations in stage 3 cutaneous melanoma patients

Prof Philippe Saiag - University of Versailles, Versailles, France

Prognostic value of BRAFV600 mutations in stage 3 cutaneous melanoma patients ( Prof Philippe Saiag - University of Versailles, Versailles, France )

What are the prognostic values of 25-hydroxyvitamin D3 levels at diagnosis and follow-up?

Prof Philippe Saiag - University of Versailles, Versailles, France

What are the prognostic values of 25-hydroxyvitamin D3 levels at diagnosis and follow-up? ( Prof Philippe Saiag - University of Versailles, Versailles, France )

Anti-PD1 or tyrosine kinase inhibitors?

Dr Mark Middleton - University of Oxford, Oxford, UK

Anti-PD1 or tyrosine kinase inhibitors? ( Dr Mark Middleton - University of Oxford, Oxford, UK )

New drugs and new trials in melanoma

Prof Jean-Jacques Grob - Marseille University, Marseille, France

New drugs and new trials in melanoma ( Prof Jean-Jacques Grob - Marseille University, Marseille, France )

Highlights of EADO 2015

Prof Jean-Jacques Grob - Marseille University, Marseille, France

Highlights of EADO 2015 ( Prof Jean-Jacques Grob - Marseille University, Marseille, France )

Disruptive technologies in cancer

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

Disruptive technologies in cancer ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )

Latest from the CoBRIM study

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

Latest from the CoBRIM study ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )

Anti-PD-1 or anti-CTLA-4 in first line therapy?

Prof Claus Garbe - University of Tübingen, Tübingen, Germany

Anti-PD-1 or anti-CTLA-4 in first line therapy? ( Prof Claus Garbe - University of Tübingen, Tübingen, Germany )

Long response and long responders in melanoma immunology

Prof Georgina Long - University of Sydney, Sydney, Australia

Long response and long responders in melanoma immunology ( Prof Georgina Long - University of Sydney, Sydney, Australia )

What is the real role of UV in melanoma?

Dr Amaya Viros - The University of Manchester, Manchester, UK

What is the real role of UV in melanoma? ( Dr Amaya Viros - The University of Manchester, Manchester, UK )

The Co-BRIM study: Quality-of-life assessment in patients with metastatic melanoma

Prof Brigitte Dreno - Nantes University Hospital, Nantes, France

The Co-BRIM study: Quality-of-life assessment in patients with metastatic melanoma ( Prof Brigitte Dreno - Nantes University Hospital, Nantes, France )

Benefit and risk analysis from the phase III OPTiM trial

Dr Kevin Harrington - Institute of Cancer Research, London, UK

Benefit and risk analysis from the phase III OPTiM trial ( Dr Kevin Harrington - Institute of Cancer Research, London, UK )

Progress in targeted therapy of melanoma

Prof Keith Flaherty - Massachusetts General Hospital, Boston, USA

Progress in targeted therapy of melanoma ( Prof Keith Flaherty - Massachusetts General Hospital, Boston, USA )

Metastatic melanoma: Patient-reported outcomes from the KEYNOTE-002 study

Prof Dirk Schadendorf - University of Duisburg-Essen, Essen, Germany

Metastatic melanoma: Patient-reported outcomes from the KEYNOTE-002 study ( Prof Dirk Schadendorf - University of Duisburg-Essen, Essen, Germany )

Melanoma prevention: Do we need sunlight for vitamin D?

Prof Julia A Newton-Bishop - University of Leeds, Leeds, UK

Melanoma prevention: Do we need sunlight for vitamin D? ( Prof Julia A Newton-Bishop - University of Leeds, Leeds, UK )

Why is screening for melanoma important?

Prof Iris Zalaudek - Medical University of Graz, Graz, Austria

Why is screening for melanoma important? ( Prof Iris Zalaudek - Medical University of Graz, Graz, Austria )

Management of acute metastatic melanoma

Dr Paul Lorigan - The Christie NHS Foundation Trust, Manchester, UK

Management of acute metastatic melanoma ( Dr Paul Lorigan - The Christie NHS Foundation Trust, Manchester, UK )

How should we handle talimogene laherparepvec (T-VEC)?

Prof Axel Hauschild - University of Kiel, Kiel, Germany

How should we handle talimogene laherparepvec (T-VEC)? ( Prof Axel Hauschild - University of Kiel, Kiel, Germany )

New challenges in drug combination and strategies

Dr Paul Lorigan - The Christie NHS Foundation Trust, Manchester, UK

New challenges in drug combination and strategies ( Dr Paul Lorigan - The Christie NHS Foundation Trust, Manchester, UK )

Targeting N-RAS mutated tumours

Prof Axel Hauschild - University of Kiel, Kiel, Germany

Targeting N-RAS mutated tumours ( Prof Axel Hauschild - University of Kiel, Kiel, Germany )

HVEM expression in melanoma metastasis: prognosis correlation

Prof Daniel Olive - Marseilles Cancer Research Center, Marseilles, France

HVEM expression in melanoma metastasis: prognosis correlation ( Prof Daniel Olive - Marseilles Cancer Research Center, Marseilles, France )

Vemurafenib in patients with BRAF600 mutation–positive metastatic melanoma

Prof Axel Hauschild - University of Kiel, Kiel, Germany

Vemurafenib in patients with BRAF600 mutation–positive metastatic melanoma ( Prof Axel Hauschild - University of Kiel, Kiel, Germany )

More from ecancer